Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Reducing Hypoglycemia Fear in Parents of Young Children With Type 1 Diabetes (REDCHiP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03879642
Recruitment Status : Completed
First Posted : March 19, 2019
Results First Posted : January 14, 2022
Last Update Posted : January 25, 2022
Children's Mercy Hospital Kansas City
Information provided by (Responsible Party):
University of Kansas Medical Center

Brief Summary:
Pilot of a novel video-based telemedicine intervention to reduce fear of hypoglycemia in parents of young children with type 1 diabetes.

Condition or disease Intervention/treatment Phase
Parents Behavioral: REDCHiP Not Applicable

Detailed Description:
This was a two group randomized controlled study using a wait-list control design. All participating parents had the opportunity to receive 10 video-based telemedicine sessions administered over 13 weeks. Study assessments took place at baseline, post-treatment, and 3 month followup. Study outcomes included parent reported hypoglycemia fear, parenting stress, diabetes distress, and child glycated hemoglobin.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 43 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: randomized control pilot using a waitlist control group
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Reducing Hypoglycemia Fear in Parents of Young Kids Via Video-based Telemedicine
Actual Study Start Date : October 1, 2015
Actual Primary Completion Date : October 1, 2018
Actual Study Completion Date : March 2019

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: REDCHiP
10 week video-based telemedicine intervention to reduce parents hypoglycemia fear
Behavioral: REDCHiP
10 week video-based telemedicine intervention to reduce hypoglycemia fear

No Intervention: Waitlist
10 week no intervention to provide waitlist control condition

Primary Outcome Measures :
  1. Hypoglycemia Fear Survey [ Time Frame: absolute value at post-treatment (week 14) ]
    Hypoglycemia Fear Survey-Parents of Young Children. This is a measure of parents' perceived hypoglycemia fear. Higher scores suggest greater fear (worse outcome). Total possible range: 26-130.

Secondary Outcome Measures :
  1. Child Hemoglobin A1c [ Time Frame: absolute value at post-treatment (week 14) ]
    Child hemoglobin A1c- biological marker of glycemic control

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   1 Year to 6 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Parents of children, between 1-6 years old, with type 1 diabetes for at least 6 months, on either multiple daily injections or an insulin pump, and parents speak English

Exclusion Criteria:

  • Families of children who are older than 6 years-old and or do not have type 1 diabetes; children follow a conventional insulin regimen
  Study Documents (Full-Text)

Documents provided by University of Kansas Medical Center:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: University of Kansas Medical Center Identifier: NCT03879642    
Other Study ID Numbers: R21HD081502 ( U.S. NIH Grant/Contract )
First Posted: March 19, 2019    Key Record Dates
Results First Posted: January 14, 2022
Last Update Posted: January 25, 2022
Last Verified: January 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Glucose Metabolism Disorders
Metabolic Diseases